ipg11406
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 24, 2024 (NCT06255834)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
GPR160 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06717815 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Nanjing Immunophage Biotech Co., Ltd |
| NCT06255834 | Phase 1 | Feb 24, 2024 | Nanjing Immunophage Biotech Co., Ltd, Zhejiang University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Immunophage Biotech Co., Ltd | For profit | 2 | 2 | 2 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1